Background: Anaplastic thyroid carcinoma (ATC) and metastatic poorly differentiated thyroid
carcinomas (PDTCs) are rare aggressive malignancies with poor overall survival (OS) …

Background Anaplastic thyroid carcinoma (ATC) is a rare but deadly form of thyroid cancer.
Kinase inhibitors kinase inhibitors have shown clinical efficacy in the management of ATC …

PURPOSE Anaplastic thyroid cancer (ATC), an aggressive malignancy, is associated with a
poor prognosis and an unmet need for effective treatment, especially for patients without …

Background Lenvatinib has been approved by regulatory agencies in Japan, the United
States, and the European Union for treatment of radioiodine-refractory differentiated thyroid …

Patients with anaplastic thyroid cancer (ATC) have an extremely poor prognosis despite
multimodal therapy with surgery and chemoradiation. Lenvatinib, a multi‐targeted tyrosine …

Background: Patients with anaplastic thyroid cancer (ATC) have a dismal prognosis, despite
systemic cytotoxic chemotherapy. The objective of this study was to investigate the efficacy …

6512 Background: Lenvatinib is an approved therapy for patients with RAIR DTC. While the
overall response rate (ORR) is high, few patients achieve a complete response (CR) and …

Chemotherapy with or without radiation is the standard therapy for anaplastic thyroid cancer
(ATC), although the response rate is not high and not durable. We describe a 62‐year‐old …

Aim: To investigate the safety and efficacy of lenvatinib in advanced thyroid cancer.
Patients/methods: In this Phase II study, 51 Japanese patients with radioiodine-refractory …

Background: Anaplastic thyroid cancer (ATC) has poor prognosis with median overall
survival (OS) of∼ 6 months. We previously reported high PD-1/PDL-1 staining in ATC …